Kornimate/medical-research-clean huggingface dataset:
bonds between circulating tumoral adn (ctdna) and the development of peritoneal carcinomatosis for patients under pipac

Conditions: Peritoneal Carcinomatosis

Summary: pipadn is a pilot monocentric, study with a total duration of 42 months. the purpose of this study is to describe the variation of plasma ctdna concentration between the 1st and the 3rd pipac session in patients with peritoneal carcinomatosis. the improvement of life quality with this type of treatment will also be evaluated though the eortc qlq-c30 survey. each patient will have three pipac sessions spaced 6 to 8 weeks apart. two blood samples will be taken during the first 3 pipac sessions, one the day before each procedure and a second one 24 hours afterwards. the eortc qlq 30 survey will be completed by patients during the pre-operative consultation and at each post-operative consultation (about 3 weeks after pipac sessions).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * who 0 to 2 * patient with cancer in the form of peritoneal carcinosmatois not eligible for cytoreduction surgery * a histological diagnosis of the primary tumor or peritoneal carcinomatosis is essential. * patient with an indication for pipac for any reason (whether as part of a clinical research protocol or not). patients with prior treatment with pipac are eligible. * patients with abdominal metastases or a single metastasis regardless of location (oligometastasis). * for patients of childbearing age need for an effective method of contraception * informing patients and obtaining informed consent, dated and signed. * patient affiliated with a social security scheme exclusion criteria: * age \< 18 years old * who \> 3 * patient who may benefit from cytoreduction surgery * patient with a contraindication to pipac * extra peritoneal disease with the exception of oligometastatic disease * persons deprived of liberty or under guardianship (including curatorship) * impossibility to undergo the medical follow-up of the trial for social, geographical or psychological reasons. * for patients of childbearing age without an effective method of contraception * woman who is pregnant, likely to be pregnant, or breastfeeding

Keywords: pipac peritoneal carcinomatosis circulating tumour dna quality of life
use of bevacizumab to modulate the outcomes of trabeculectomy surgery

Conditions: Glaucoma

Summary: vascular epithelial growth factor (vegf) plays a critical role in vessel growth and wound healing. bevacizumab, a non specific vegf inhibitor, has been successfully used for the treatment of eye diseases associated with neovascularization. the purpose of this randomized study is 1) to investigate the effects of intraoperative subtenon injection of bevacizumab on the outcomes of trabeculectomy surgery. 2) to measure plasma and aqueous levels of vegf and assess its association with the outcomes of trabeculectomy surgery. trabeculectomy surgery, where a small drainage canal is created at the front of the eye, is the most common glaucoma surgery performed worldwide. the goal of the surgery is to control intraocular pressure. failure of this procedure is most commonly caused by excessive scarring of the surgical site. if scarring occurs, the drainage canal can close. by adding bevacizumab at the time of surgery, wound healing may be slowed and surgical failure prevented. the results of this study will be helpful in the future development of new more effective and safe surgical techniques for treatment of glaucoma. patients who have given informed consent are randomized into two groups. one group receives standard of care for trabeculectomy surgery and the other group receives standard of care plus an injection of bevacizumab at the surgery site. both groups have a one time collection of ocular fluid and a blood sample taken from a vein in the arm. after surgery, patients are seen by their study doctor six times in the following year. at these visits measurements are taken of their visual acuity, eye pressure and blood pressure. the doctor does a clinical exam and at months six and twelve photographs of the patients' eye are taken.


Eligibility criteria:
inclusion criteria: * any type of glaucoma, except neovascular or inflammatory * patients requiring trabeculectomy or combined cataract surgery with trabeculectomy surgery exclusion criteria: * younger than 30 years of age * previous ocular surgeries excepting cataract surgeries * patients who have had or present with intraocular inflammation * neovascular glaucoma * patients who are aphakic * diabetic retinopathy

Keywords: trabeculectomy glaucoma surgery bevacizumab vascular endothelial growth inhibitor glaucoma
study of optimal posology of gonadotrophins in patients with insufficient ovarian response due to age

Conditions: Infertility

Summary: in in vitro fertilization (ivf) treatment, poor responder patients of more than 38 years old are randomized prospectively into two dosages of gonadotrophins. the outcome of treatment will be analyzed.

women \> 38 years, who had an insufficient response to stimulation with regular (for age) posology of 225 iu of gonadotrophins (urinary or recombinant), in an agonist protocol will be randomized prospectively into 2 groups: 300 iu versus 450 iu of gonal-f® administered in a short agonist protocol. insufficient response is defined as: development of ≤ 4 mature follicles (of ≥ 16 mm) at time of hcg administration. patient can be eligible for several cycles in same protocol.

Eligibility criteria:
inclusion criteria: * women \> 38 years with insufficient response to stimulation with 225 iu of gonadotrophins (urinary or recombinant), in an agonist protocol. * insufficient response is defined as: development of ≤ 4 mature follicles (of ≥ 16 mm) at time of hcg administration. * patient can be eligible for several cycles in same protocol. exclusion criteria: * patients who already received doses \> 225 iu * patients older than 42 years * patients with basal fsh concentrations ≥ 15 mu/ml at day 3

Keywords: ivf poor responder recfsh fertilization in vitro poor responders
m7824 with ccrt in unresectable stage iii non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer

Summary: the main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (ccrt) plus m7824 followed by m7824 compared to ccrt plus placebo followed by durvalumab.


Eligibility criteria:
inclusion criteria: * participants must have histologically documented nsclc who present with stage iii locally advanced, unresectable disease (international association for the study of lung cancer staging manual in thoracic oncology * participants with tumor harboring an epidermal growth factor receptor (egfr) sensitizing (activating) mutation, anaplastic lymphoma kinase (alk) translocation, ros-1 rearrangement are eligible. * participants must have adequate pulmonary function defined as a forced expiratory volume in 1 second (fev1) greater than equals to (\>=) 1.2 liters or \>= 50% of predicted normal volume measured within 3 weeks prior to randomization. * adequate hematological, hepatic and renal function as defined in the protocol * contraceptive use by males or females will be consistent with local regulations on contraception methods for those participating in clinical studies exclusion criteria: * participants with mixed small cell with non-small cell lung cancer histology * recent major surgery within 4 weeks prior to entry into the study * significant acute or chronic infections including human immunodeficiency virus (hiv) or known acquired immunodeficiency syndrome, active hepatitis b virus (hbv) or hepatitis c virus (hcv) infection and active tuberculosis * chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization * active autoimmune disease that has required systemic treatment in past 1 year (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) * any prior systemic cytotoxic chemotherapy for their nsclc or any antibody or drug targeting t-cell coregulatory proteins

Keywords: non-small cell lung cancer bintrafusp alfa (proposed inn) m7824 durvalumab stage iii intr@pid lung 005
improvement in postoperative pain outcomes

Conditions: Acute Post Operative Pain

Summary: this is an observational study project aims at improving postoperative pain outcomes by evaluating the current status of postoperative pain managements in the institution. then the investigators will compare the results by internal and external benchmarking. then they will suggest recommendations to improve the current situation of postoperative pain management.

at least half of the patients suffer from moderate to severe post-operative pain. the price of poorly managed pain is high: pain impedes recovery, causes suffering and prolongs the hospital stay. pain out provides tools for measurement, feedback and benchmarking of pain treatment quality in order to improve patient care. a research project that aims at improving postoperative pain treatment outcomes by evaluating the current status of postoperative pain managements in our institution. then the investigators compare the results by internal and external benchmarking. then suggest recommendations to improve the current situation of postoperative pain management. parameters include" patient's data pain assessments by using the visual analogue score of 11 point (from "0" no pain - "10" worst pain) will be evaluated as the following: worst pain since surgery, least pain since surgery, pain score at rest. pain score during movements in bed, pain score during deep breathing and coughing, how often the severe pain since surgery (%), does the pain interfere with sleeping pattern, and the side effects.

Eligibility criteria:
inclusion criteria: * postoperative patients during the first 24 hours of surgery (day 1) * male and females * adults exclusion criteria: * patient refusal * drug abusers and addicts * major significant systemic diseases * language barriers

Keywords: acute postoperative pain orthopedic surgery general surgery obs/gyn surgery neurosurgery bariatric surgery thoracic surgery opioids nsaids regional analgesia
benefit of roux-en-y (r-y) reconstruction after pancreaticoduodenectomy

Conditions: Pancreatic Cancer

Summary: one of the most common complications of pancreaticoduodenectomy (pd) is delayed gastric emptying (dge), otherwise known as "gastroparesis," which is not fatal but results in prolonged hospital stay and increased hospital costs. delayed gastric emptying is defined as nasogastric decompression after postoperative day (pod) 10 or a failure to tolerate a regular diet after pod 14. the incidence of dge has been reported to range from 5% to 72%.

we hypothesized that the hand-sewn, two-layered, or continuous suture, could induce anastomotic edema to indeed the afferent peristalsis, which is one of the causes of dge.

Eligibility criteria:
inclusion criteria: * these patients were to undergo elective pancreatic head resection for the treatment of periampullary mass exclusion criteria: * a body weight loss greater than 10% during the six months prior to surgery * the presence of distant metastases * seriously impaired function of vital organs due to respiratory, renal or heart disease

Keywords: pancreaticoduodenectomy reconstruction
reinfection after eradication of helicobacter pylori infection

Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori); Eradication Therapy of Helicobacter Pylori; Detection of Helicobacter Pylori

Summary: helicobacter pylori is closely related with gastritis, peptic ulcer, gastric cancer and gastric malt lymphoma, and it may participate in a variety of parenteral diseases. infection rates of helicobacter pylori is still high, so effectively eradication is necessary. at present, the eradication therapy has achieved very good curative effect. however, relapse after eradication is unoptimistic. this study has made an analysis for reinfection after eradication of helicobacter pylori infection include the retrospective and prospective studies, aims to explore the epidemiological data and related risk factors of hp reinfection in china.

in the retrospective study,we choose the people received regular eradication therapy, successfully eradicated helicobacter pylori more than six months, but 4 to 8 weeks after drug withdrawal ,the detection result of helicobacter pylori were negative to ensure that the results of the study is the reinfection, not residual. even more noteworthy is during the treatment and detection again, the patients must not received any eradication therapy of hp. what's more , before the detection, they also has not used antibiotics, bismuth agent and the traditional chinese medicine with antibacterial effect in 1 monthor and has not used h2ra and ppi in 2 weeks to prevent affecting the accuracy of the results. at the same time, we also investigated the patient's general situation, conomic conditions, living conditions, personal health and lifestyle to explore related risk factors of hp reinfection in china. in the prospective study, we detected hp by c-ubt after regular eradication therapy of hp for 4 weeks, 8 weeks and 6 months to prospect the reinfection of hp.it also can make up the defects of retrospective study.

Eligibility criteria:
inclusion criteria: -1、retrospective study： 1. received regular eradication therapy, 4 to 8 weeks after drug withdrawal , detected of helicobacter pylori and the results were negative 2. eradication program and original disease is unlimited 3. without any eradication therapyof hp during the treatment and detection again 4. before the detection has not used antibiotics, bismuth agent and the traditional chinese medicine with antibacterial effect in 1 monthor and has not used h2ra and ppi in 2 weeks. 2、prospective study 1. infected with h. pylori that detected by c-ubt 2. with out alimentary tract hemorrhage,ulceration and complications of eradication 3. eradication program and original disease is unlimited exclusion criteria: 1. pregnancy or breast-feeding women 2. with the major disease which would influence the research such as liver disease, heart disease, kidney disease, malignant tumor and alcohol poisoning 3. participated in other drug research in the past three months 4. the patient can't express himself correctly such as mental illness and severe neurosis and can't cooperation this test

Keywords: reinfection eradication therapy c-urea breath test helicobacter pylori
impact of the implementation of ckd coordination function on dialysis initiation frequency in emergency

Conditions: Chronic Kidney Disease

Summary: kidney failure is a major public health problem. rein registry shows that 33% of patients treated in renal replacement therapy for esrd start dialysis in emergency. unscheduled care is associated with an increased risk of morbidity and mortality, with less access to off dialysis center and kidney transplant. in addition, the emergency management has an impact on the organization of health structures. the high authority of health in 2012 issued a "care pathway guide" aimed "to report in this process of the multidisciplinary nature of the management and coordination of principles and procedures for the chronic renal failure and cooperation between professionals involved. " a function of coordinator of the chronic renal disease was set up in service since may 2013. investigators propose to carry out a study to value its impact on the start of the dialysis in emergency and hypothesize that this feature innovative in france improves the patient pathway and thus reduce support emergency frequency of esrd. the objective of this study is to show the improvement of the quality of care for terminally chronic renal failure patients. this is to evaluate an experiment aimed to facilitate a complex care path. if this experiment is successful, it could form part of "advanced practice".


Eligibility criteria:
inclusion criteria: * patients over 18 years with terminal chronic renal failure enrolled in the course of care exclusion criteria: * patients under 18 years * patient off course * patient beginning dialysis with a method of transition

Keywords: emergency coordination dialysis
clinical investigation to assess the clinical performance of the lumbacure® intervention on chronic low back pain patients.

Conditions: Chronic Low Back Pain

Summary: low back pain (lbp) is one of the common causes of morbidity worldwide, with a one-month prevalence of 23.3 %. number of people with lbp reached 577 million people in 2020. lbp has been the leading cause of years lived with disability from 1990 to 2017. the highest incidence of lbp is in people in their third decade of age. lbp is a complex disease difficult to treat as most of these cases (80 - 90 %) are classified as non-specific meaning that the pain cannot be attributed to any specific injury or pathology. until now exercise therapy is commonly used as the treatment of choice in the revalidation program of lbp. the aim of physical treatment is to improve function and prevent disability from getting worse. lumbacure® is a robotic system driven by a proprietary movement algorithm to induce a specific and controlled mobilization of the hips and the low back in patient requiring treatment by physical exercises due to orthopedic disorder, especially low back pain. the investigation include an intervention period of 4 weeks the main objective is to compare the impact on disability (oswestry disability index) and movement performance of the interventions (lumbacure® vs physical exercises supervised by the physiotherapist) in two parallel groups of patients suffering from chronic low back pain. the investigation includes an intervention period of 4 weeks and a follow-up period of 6 months (post intervention period).


Eligibility criteria:
inclusion criteria: * chronic non-specific lbp (without red flag) * patient did not increase, on a long-term basis, his/her regular physical activity in the past 2 months. * lbp is the principal musculoskeletal condition * aged between 18 and 65 years old * able to read and understand questionnaires and communicate with the physiotherapist. * average back pain intensity over the last week above 2, assessed on numerical pain rating scale from 0 to 10 anchored with "no pain" at 0 and "worst pain imaginable " at 10. * odi score \> 20 exclusion criteria: * suspected or confirmed serious pathology (i.e infection, fracture, cancer, inflammatory arthritis, ....) * radicular pain * radiculopathy * cognitive impairment that precludes participant from consenting, completing investigation questionnaires or complying with recommendations * previous spine surgery in the last 3 months * pregnant women * body weight \> 120 kg * neurological disease * fibromyalgia
oxygen toxicity in the resuscitation in extremely premature infants

Conditions: Birth Asphyxia; Premature Birth

Summary: the investigators hypothesize that using low oxygen concentrations during resuscitation of extremely premature infants will avoid oxidative stress derived damage and improve outcome.

this is a prospective randomized trial enrolling premature infants of less than 28 weeks gestation. patients are randomly assigned to become resuscitation with an initial oxygen inspiratory fraction (fio2) of 30% or 90%. main objective is to reach a target saturation of 85% at 15 min of life. immediately after birth pre-and-postductal pulse oximeters are set and oxygen saturation (spo2) continuously monitored and registered as long as the patient requires oxygen supplementation. fio2 is stepwise adjusted (increased or decreased 10%) every 90 sec according to heart rate, spo2 and responsiveness. blood samples are drawn from umbilical cord and at day 1, 2 and 7 from peripheral vein to determine oxidative stress markers (gsh, gssg), angiogenic factors (vegf, vegf receptors, angiopoietin), pro-inflammatory markers (il8, tnf alfa) and pro-apoptotic markers (fas ligand; cytochrome c). urine is collected every day during the first week of life to determine oxidative stress markers (8-oxo-dg; o-tyrosine; f2 isoprostanes; isofurans). babies are followed in the nicu and clinical condition recorded. serial examinations for rop and auditory evoked potentials will be performed. neurodevelopmental outcome is evaluated at 2 years of postnatal life. main outcome: achievement of a target saturation of 85% at 15 min of life. secondary outcomes: acute complications during delivery; chronic complications (bpd, rop, ipvh); mortality in the neonatal period.

Eligibility criteria:
inclusion criteria: * prematurity of less than 28 weeks gestation exclusion criteria: * severe malformations * chromosomopathies * informed consent not signed

Keywords: asphyxia resuscitation oxidative stress prematurity follow up
clinical trial for evaluating sage-based mouthrinse

Conditions: Stomal Bleeding; Stomatitis, Denture; Tooth Staining; Satisfaction

Summary: the investigators aim to evaluate a sage-based mouthrinse (dr. hauschka med, mundspülung salbei) whether it is less or equal effective in alleviating inflammatory signs of intra-oral mucosa and gingiva than an water/alcohol-based taste adjusted placebo in patients dependent on adl. randomization in treatment a (mouthwash with active agent, n=24) or treatment b (placebo mouthwash, n=24) supervised use of mouthwash a or mouthwash b over 6 weeks 1x/day additional to habitual oral hygiene protocol. the main outcome parameter will be sulcus bleeding index sbi.

a sage-based mouthrinse based on an extract from salvia officinalis in a composition with extracts from althaea officinalis, aesculus hippocatanum bark and essential oils might comprise an alternative to conventional antimicrobial mouthrinses, which might exhibit important side effects. thus the aim of the current study is to test the null-hypothesis h0: a sage-based mouthrinse (dr. hauschka med, mundspülung salbei, wala heilmittel gmbh, dorfstraße 1, 73087 bad boll/eckwälden, germany) is less or equal effective in alleviating inflammatory signs of intra-oral mucosa and gingiva than an water/alcohol-based taste adjusted placebo. the placebo and the sage-based mouthrinse will be manufactured according to eu-kosmetik-verordnung 1223/2009 and provided by wala heilmittel gmbh, dorfstraße 1, 73087 bad boll/eckwälden, germany together with the necessary safety documentation. the placebo will be an alcohol/ water based solution with a similar taste to the tested mouthrinse. the main outcome parameter will be sulcus bleeding index sbi. among others, the main secondary outcome parameters will be oral health related quality of life as assessed with the ohip-14 g questionnaire, the xerostomia inventory and a tooth staining index.

Eligibility criteria:
inclusion criteria: * able to give informed consent, i.e. no legal guardian appointed * willing to participate * depended on their adls (iadl)(24) * sulcus bleeding index (sbi) \> 50% exclusion criteria: * allergy to one of the components * edentulous * alcohol dependency * prescription of antibiotics and/ or immunosuppressives (e.g. glucocorticoids) anti-inflammatory mouthrinse -